EGFR and non-small cell lung carcinoma: In the multicenter, real-world Reiwa Study in Japan, 344 (59.0%) of 583 EGFR mutant advanced NSCLC patients had disease progression and 20.1% of them had oligoprogression and 54.5% patients who received first-line osimertinib developed progressive disease and 156 (45.4%) of them had oligoprogressive disease (Watanabe et al., 2024).